Proteomic Profiling Drug-Induced Apoptosis in Non-Small Cell Lung Carcinoma: Identification of RS/DJ-1 and RhoGDIα

Cancer Research

Volumn 63, Issue 20, 2003, Pages 6928-6934

  MacKeigan, Jeffrey P ^a,b   Clements, Casey M ^a,b   Lich, John D ^a,b   Pope, R Marshall ^b   Hod, Yaacov ^c   Ting, Jenny P Y ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; COMPLEMENTARY DNA; GUANOSINE DIPHOSPHATE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NUCLEIC ACID; PACLITAXEL; PROTEIN; RHO FACTOR; RHO GUANOSINE DIPHOSPHATE DISSOCIATION INHIBITOR ALPHA PROTEIN; RNA; RNA 18S; RNA BINDING REGULATORY SUBUNIT PROTEIN; UNCLASSIFIED DRUG; UO 126;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE; CELL DEATH; CONTROLLED STUDY; DRUG TARGETING; ENZYME INHIBITION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEOMICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA BINDING; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BUTADIENES; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; ENZYME INHIBITORS; GUANINE NUCLEOTIDE DISSOCIATION INHIBITORS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; MAP KINASE KINASE KINASE 1; NITRILES; ONCOGENE PROTEINS; PACLITAXEL; PROTEIN-SERINE-THREONINE KINASES; PROTEOMICS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 0142157658     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Kerr, J. F., Wyllie, A. H., and Currie, A. R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer, 26: 239-257, 1972.
2. Wyllie, A. H., Kerr, J. F., and Currie, A. R. Cell death: the significance of apoptosis. Int. Rev. Cytol., 68: 251-306, 1980.
3. Slater, A. F., Kimland, M., Jizing, S. A., and Orrenius, S. Constitutive nuclear NF κB/rel DNA-binding activity of rat thymocytes is increased by stimuli that promote apoptosis, but not inhibited by pyrrolidine dithiocarbamate. Biochem. J., 312: 833-838, 1995.
4. Wang, C. Y., Mayo, M. W., and Baldwin, A. S., Jr. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science (Wash. DC), 274: 784-787, 1996.
5. Wang, C. Y., Cusack, J. C., Jr., Liu, R., and Baldwin, A. S., Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat. Med., 5: 412-417, 1999.
6. MacKeigan, J. P., Collins, T. S., and Ting, J. P-Y. MEK inhibition enhances paclitaxel-induced tumor apoptosis. J. Biol. Chem., 275: 38953-38956, 2000.
7. Torres, K., and Horwitz, S. B. Mechanisms of Taxol-induced cell death are concentration dependent. Cancer Res., 58: 3620-3626, 1998.
8. Xia, Z., Dickens, M., Raingeaud, J., Davis, R. J., and Greenberg, M. E. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science (Wash. DC), 270: 1326-1331, 1995.
9. Gupta, K., Kshirsagar, S., Li, W., Gui, L., Ramakrishnan, S., Gupta, P., Law, P. Y., and Hebbel, R. P. VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling. Exp. Cell Res., 247: 495-504, 1999.
10. Yu, C., Wang, S., Dent, P., and Grant, S. Sequence-dependent potentiation of paclitaxel-mediated apoptosis in human leukemia cells by inhibitors of the mitogen-activated protein kinase kinase/mitogen-activated protein kinase pathway. Mol. Pharmacol., 60: 143-154, 2001.
11. Herrera, R., and Sebolt-Leopold. J. S. Unraveling the complexities of the Raf/MAP kinase pathway for pharmacological intervention. Trends Mol. Med., 8: S27-S31, 2002.
12. Sebolt-Leopold, J. S. Development of anticancer drugs targeting the MAP kinase pathway. Oncogene, 19: 6594-6599, 2000.
13. Sebolt-Leopold, J. S., Dudley, D. T., Herrera, R., Van Becelaere, K., Wiland, A., Gowan, R. C., Tecle, H., Barrett, S. D., Bridges, A., Przybranowski, S., et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat. Med., 5: 810-816, 1999.
14. Sivaraman, V. S., Wang, H., Nuovo, G. J., and Malbon, C. C. Hyperexpression of mitogen-activated protein kinase in human breast cancer. J. Clin. Investig., 99: 1478-1483, 1997.
15. Mandell, J. W., Hussaini, I. M., Zecevic, M., Weber, M. J., and Van den Berg, S. R. In situ visualization of intratumor growth factor signaling: immunohistochemical localization of activated ERK/MAP kinase in glial neoplasms. Am. J. Pathol., 153: 1411-1423, 1998.
16. Mansour, S. J., Matten, W. T., Hermaun, A. S., Candia, J. M., Rong, S., Fukasawa, K., Vande Woude, G. F., and Ahn, N. G. Transformation of mammalian cells by constitutively active MAP kinase kinase. Science (Wash. DC), 265: 966-970, 1994.
17. Lewis, T. S., Hunt, J. B., Aveline, L. D., Jonseher, K. R., Louie, D. F., Yeh, J. M., Nahreini, T. S., Resing, K. A., and Ahn, N. G. Identification of novel MAP kinase pathway signaling targets by functional proteomics and mass spectrometry. Mol. Cell, 6: 1343-1354, 2000.
18. Hod, Y., Pentyala, S. N., Whyard, T. C., and El-Maghrabi, M. R. Identification and characterization of a novel protein that regulates RNA-protein interaction. J. Cell. Biochem., 72: 435-444, 1999.
19. McDaid, H. M., and Horwitz, S. B. Selective potentiation of paclitaxel (Taxol)-induced cell death by mitogen-activated protein kinase kinase inhibition in human cancer cell lines. Mol. Pharmacol., 60: 290-301, 2001.
20. Wang, H., Cao, R., Xia, L., Erdjument-Bromage, H., Borchers, C., Tempst, P., and Zhang, Y. Purification and functional characterization of a histone H3-lysine 4-specific methyltransferase. Mol. Cell, 8: 1207-1217, 2001.
21. Nagakubo. D., Taira, T., Kitaura, H., Ikeda, M., Tamai, K., Iguchi-Ariga, S. M. M., and Ariga, H. DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras. Biochem. Biophys. Res. Commun., 231: 509-513, 1997.
22. Elbashir, S. M., Harborth, J., Lendeckel, W., Yalein, A., Weber, K., and Tuschl, T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (Lond.), 411: 494-498, 2001.
23. Elbashir, S. M., Lendeckel, W., and Tuschl, T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev., 15: 188-200, 2001.
24. Harborth, J., Elbashir, S. M., Bechert, K., Tuschl, T., and Weber, K. Identification of essential genes in cultured mammalian cells using small interfering RNAS. J. Cell Sci., 114: 4557-4565, 2001.
25. Makin, G., and Dive, C. Apoptosis and cancer chemotherapy. Trends Cell Biol., 11: S22-S26, 2001.
26. Makin, G., and Dive, C. Modulating sensitivity to drug-induced apoptosis: the future for chemotherapy? Breast Cancer Res., 3: 150-153, 2001.
27. Washburn, M. P., Wolters, D., and Yates, J. R., III. Large-scale analysis of the yeast protcome by multidimensional protein identification technology. Nat. Biotechnol., 19: 242-247, 2001.
28. Link, A. J., Eng, J., Schieltz, D. M., Carmack, E., Mize, G. J., Morris, D. R., Garvik, B. M., and Yates, J. R., III. Direct analysis of protein complexes using mass spectrometry. Nat. Biotechnol., 17: 676-682, 1999.
29. Gygi, S. P., Rist, B., Gerber, S. A., Turecek, F., Gelb. M. H., and Aebersold, R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat. Biotechnol., 17: 994-999, 1999.
30. Bonifati, V., Rizzu, P., van Baren, M. J., Schaap, O., Breedveld, G. J., Krieger, E., Dekker, M. C., Squitieri, F., Ibanez, P., Joosse, M., et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset Parkinsonism. Science (Wash. DC), 299: 256-259, 2003.
31. Wilson, M. A., Collins, J. L., Hod, Y., Ringe, D., and Petsko, G. A. The 1.1-Å resolution crystal structure of DJ-1, the protein mutated in autosomal recessive early onset Parkinson's disease. Proc. Natl. Acad. Sci. USA, 100: 9256-9261, 2003.
32. Le Naour, F., Misek, D. E., Krause, M. C., Deneux, L., Giordano, T. J., Scholl, S., and Hanash, S. M. Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer. Clin. Cancer Res., 7: 3328-3335, 2001.
33. Wan, J., Wang, J., Cheng, H., Yu, Y., Xing, G., Oiu, Z., Qian, X., and He, F. Proteomic analysis of apoptosis initiation induced by all-trans retinoic acid in human acute promyelocytic leukemia cells. Electrophoresis, 22: 3026-3037, 2001.
34. Kovarova, H., Hajduch, M., Korinkova, G., Halada, P., Krupickova, S., Gouldsworthy, A., Zhelev, N., and Strnad, M. Proteomics approach in classifying the biochemical basis of the anticancer activity of the new olomoucine-derived synthetic cyelin-dependent kinase inhibitor, bohemine. Electrophoresis, 21: 3757-3764, 2000.
35. Han, H., Bearss, D. J., Browne, L. W., Calaluce, R., Nagle, R. B., and Von Hoff, D. D. Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res., 62: 2890-2896, 2002.
36. Scherle, P., Behrens, T., and Slaudt, L. M. Ly-GDI, a GDP-dissociation inhibitor of the RhoA GTP-binding protein, is expressed preferentially in lymphocytes. Proc. Natl. Acad. Sci. USA, 90: 7568-7572, 1993.
37. Adra, C. N., Manor, D., Ko, J. L., Zhu, S., Horiuchi, T., Van Aclst, L., Cerione, R. A., and Lim, B. RhoGDIγ: a GDP-dissociation inhibitor for Rho proteins with preferential expression in brain and pancreas. Proc. Natl. Acad. Sci. USA, 94: 4279-4284, 1997.
38. Jones, M. B., Krutzsch, H., Shu, H., Zhao, Y., Liotta, L. A., Kohn, E. C., and Petricoin, E. F., III. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics, 2: 76-84, 2002.